Huaren Pharmaceutical Co., Ltd. (300110.SZ)
CNY 2.9
(3.2%)
CNY 2.9
(3.2%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 699.05 Million CNY | -0.25% |
| 2022 | 700.78 Million CNY | -11.24% |
| 2021 | 789.5 Million CNY | 39.92% |
| 2020 | 564.25 Million CNY | -31.85% |
| 2019 | 827.9 Million CNY | 3.83% |
| 2018 | 797.35 Million CNY | 13.73% |
| 2017 | 701.09 Million CNY | 25.27% |
| 2016 | 559.66 Million CNY | 12.76% |
| 2015 | 496.32 Million CNY | 12.37% |
| 2014 | 441.7 Million CNY | -4.17% |
| 2013 | 460.9 Million CNY | 46.03% |
| 2012 | 315.62 Million CNY | 38.4% |
| 2011 | 228.05 Million CNY | 19.13% |
| 2010 | 191.43 Million CNY | 16.29% |
| 2009 | 164.62 Million CNY | 49.63% |
| 2008 | 110.02 Million CNY | 49.72% |
| 2007 | 73.48 Million CNY | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 120.28 Million CNY | -26.98% |
| 2024 Q3 | 91.3 Million CNY | -19.94% |
| 2024 Q1 | 164.73 Million CNY | -0.78% |
| 2023 Q3 | 183.4 Million CNY | 0.99% |
| 2023 Q4 | 166.02 Million CNY | -9.47% |
| 2023 FY | 699.05 Million CNY | -0.25% |
| 2023 Q1 | 168.01 Million CNY | -19.54% |
| 2023 Q2 | 181.61 Million CNY | 8.09% |
| 2022 FY | 700.78 Million CNY | -11.24% |
| 2022 Q2 | 137.67 Million CNY | -27.31% |
| 2022 Q3 | 164.9 Million CNY | 19.78% |
| 2022 Q4 | 208.8 Million CNY | 26.62% |
| 2022 Q1 | 189.39 Million CNY | -15.75% |
| 2021 Q3 | 214.3 Million CNY | 23.08% |
| 2021 FY | 789.5 Million CNY | 39.92% |
| 2021 Q1 | 176.27 Million CNY | 46.26% |
| 2021 Q2 | 174.1 Million CNY | -1.23% |
| 2021 Q4 | 224.81 Million CNY | 4.91% |
| 2020 FY | 564.25 Million CNY | -31.85% |
| 2020 Q3 | 159.1 Million CNY | 0.05% |
| 2020 Q4 | 120.52 Million CNY | -24.25% |
| 2020 Q1 | 125.58 Million CNY | -36.84% |
| 2020 Q2 | 159.02 Million CNY | 26.62% |
| 2019 Q3 | 211.46 Million CNY | -7.62% |
| 2019 FY | 827.9 Million CNY | 3.83% |
| 2019 Q1 | 188.67 Million CNY | -12.61% |
| 2019 Q2 | 228.9 Million CNY | 21.33% |
| 2019 Q4 | 198.85 Million CNY | -5.96% |
| 2018 Q1 | 186.4 Million CNY | -12.49% |
| 2018 FY | 797.35 Million CNY | 13.73% |
| 2018 Q4 | 215.9 Million CNY | 3.44% |
| 2018 Q2 | 186.34 Million CNY | -0.03% |
| 2018 Q3 | 208.71 Million CNY | 12.01% |
| 2017 Q3 | 188.63 Million CNY | 17.22% |
| 2017 Q4 | 213 Million CNY | 12.92% |
| 2017 FY | 701.09 Million CNY | 25.27% |
| 2017 Q2 | 160.91 Million CNY | 16.15% |
| 2017 Q1 | 138.53 Million CNY | -22.63% |
| 2016 Q4 | 179.04 Million CNY | 24.95% |
| 2016 Q1 | 109.37 Million CNY | -21.83% |
| 2016 Q2 | 127.95 Million CNY | 16.99% |
| 2016 Q3 | 143.29 Million CNY | 11.99% |
| 2016 FY | 559.66 Million CNY | 12.76% |
| 2015 FY | 496.32 Million CNY | 12.37% |
| 2015 Q2 | 133.48 Million CNY | 18.99% |
| 2015 Q3 | 110.73 Million CNY | -17.04% |
| 2015 Q4 | 139.91 Million CNY | 26.35% |
| 2015 Q1 | 112.18 Million CNY | 0.07% |
| 2014 Q3 | 120.22 Million CNY | 13.32% |
| 2014 Q4 | 112.1 Million CNY | -6.76% |
| 2014 Q1 | 103.28 Million CNY | -32.93% |
| 2014 Q2 | 106.09 Million CNY | 2.72% |
| 2014 FY | 441.7 Million CNY | -4.17% |
| 2013 Q3 | 109.01 Million CNY | 0.88% |
| 2013 Q1 | 89.83 Million CNY | -13.25% |
| 2013 Q4 | 153.99 Million CNY | 41.27% |
| 2013 FY | 460.9 Million CNY | 46.03% |
| 2013 Q2 | 108.06 Million CNY | 20.3% |
| 2012 Q2 | 75.59 Million CNY | 36.82% |
| 2012 Q4 | 103.55 Million CNY | 27.46% |
| 2012 Q1 | 55.24 Million CNY | -18.29% |
| 2012 FY | 315.62 Million CNY | 38.4% |
| 2012 Q3 | 81.24 Million CNY | 7.48% |
| 2011 FY | 228.05 Million CNY | 19.13% |
| 2011 Q3 | 57.2 Million CNY | 6.13% |
| 2011 Q2 | 53.9 Million CNY | 9.25% |
| 2011 Q4 | 67.61 Million CNY | 18.2% |
| 2011 Q1 | 49.33 Million CNY | -0.09% |
| 2010 FY | 191.43 Million CNY | 16.29% |
| 2010 Q1 | 42.75 Million CNY | -4.31% |
| 2010 Q2 | 54.66 Million CNY | 27.86% |
| 2010 Q3 | 44.64 Million CNY | -18.33% |
| 2010 Q4 | 49.38 Million CNY | 10.62% |
| 2009 Q3 | 46.73 Million CNY | 0.0% |
| 2009 Q4 | 44.67 Million CNY | -4.41% |
| 2009 FY | 164.62 Million CNY | 49.63% |
| 2008 FY | 110.02 Million CNY | 49.72% |
| 2007 FY | 73.48 Million CNY | 0.0% |